BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT00779064
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
Phase 3
Completed
- Conditions
- Oral ContraceptiveHeadachePelvic Pain
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027)Drug: Encapsulated Microgynon + Placebo
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 449
- Registration Number
- NCT00778609
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
Completed
- Conditions
- Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00771147
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Phase 4
Completed
- Conditions
- Constipation
- Interventions
- Other: Placebo, maltodextrin 500 powder for solutionDrug: Polyethylene glycol 3350
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 203
- Registration Number
- NCT00770432
BAY 77-1931 Long-term Extension From Phase II Study
Phase 2
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: BAY 77-1931
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 145
- Registration Number
- NCT00769496
Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT00768560
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
Phase 3
Completed
- Conditions
- Infection, Intra-abdominal
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 364
- Registration Number
- NCT00769171
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
Phase 2
Completed
- Conditions
- HyperphosphatemiaDialysis
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT00767637
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
Phase 3
Completed
- Conditions
- Gastric AcidHuman Experimentation
- Interventions
- Drug: Omeprazole/sodium bicarbonateDrug: omeprazole magnesium (20 mg equivalent)
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT00765206
Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Phase 4
Completed
- Conditions
- Neoplastic CNS Lesions
- Interventions
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 166
- Registration Number
- NCT00764387
© Copyright 2025. All Rights Reserved by MedPath